Тромбоз, гемостаз и реология

Tromboz, Gemostaz I Reologiya
scientific and practical journal

ISSN 2078–1008 (Print); ISSN 2687-1483 (online)
2025, Clinical cases
2025

Clinical experience with lonoctocog alfa for prophylaxis in a patient with hemophilia A: 616-005.1:616.151.514-056.7

Clinical cases
Published 2025-06-05
Tatiana A. Andreeva
Municipal Polyclinic No. 37, City Center for Treatment of Hemophilia Patients; 6а Gorokhovaya Str., Saint Petersburg 191186, Russia
СПб ГБУЗ «Городская поликлиника № 37», Городской центр по лечению больных гемофилией; Россия, 191186 Санкт-Петербург, ул. Гороховая, 6а
https://orcid.org/0000-0002-5649-325X (unauthenticated)
Olga E. Zalepukhinina
Municipal Polyclinic No. 37, City Center for Treatment of Hemophilia Patients; 6а Gorokhovaya Str., Saint Petersburg 191186, Russia
СПб ГБУЗ «Городская поликлиника № 37», Городской центр по лечению больных гемофилией; Россия, 191186 Санкт-Петербург, ул. Гороховая, 6а
Olga A. Krasheninnikova
Municipal Polyclinic No. 37, City Center for Treatment of Hemophilia Patients; 6а Gorokhovaya Str., Saint Petersburg 191186, Russia
СПб ГБУЗ «Городская поликлиника № 37», Городской центр по лечению больных гемофилией; Россия, 191186 Санкт-Петербург, ул. Гороховая, 6а
Victoriya A. Pozdnyakova
Municipal Polyclinic No. 37, City Center for Treatment of Hemophilia Patients; 6а Gorokhovaya Str., Saint Petersburg 191186, Russia
СПб ГБУЗ «Городская поликлиника № 37», Городской центр по лечению больных гемофилией; Россия, 191186 Санкт-Петербург, ул. Гороховая, 6а
Victor Yu. Petrov
Morozov Children’s City Clinical Hospital, Moscow Healthcare Department; 1/9 4th Dobryninskiy Pereulok, Moscow 119049, Russia
ГБУЗ «Морозовская детская городская клиническая больница Департамента здравоохранения города Москвы»; Россия, 119049 Москва, 4-й Добрынинский переулок, 1/9

Keywords

hemophilia A
lonoctocog alfa
hemarthrosis
hemophilic arthropathy
  Full Text

Abstract

Summary. In recent years, the choice of recombinant factor VIII products, including those for subcutaneous administration, has expanded significantly. However, in the treatment of patients with hemophilia A, a number of unresolved issues remain, primarily those related to the treatment burden for patients and their relatives, insufficient bleeding control, and progression of musculoskeletal damage. We present
a clinical case of a 38-year-old patient with severe hemophilia A, hemophilic arthropathy of the ankle and knee joints who was switched from plasma-derived FVIII product to a recombinant single-chain FVIII (lonoctocog alfa). The therapeutic modification resulted in an increased residual FVIII activity and demonstrated clinical effectiveness. No adverse events were observed during treatment. This case illustrates the high efficacy and safety of recombinant single-chain FVIII (lonoctocog alfa) for bleeding prophylaxis in a patient with hemophilia A in real world clinical practice in Russia.

For citation: Andreeva T.A., ZalepukhininaO.E., KrasheninnikovaO.A., PozdnyakovaV.A., PetrovV.Yu. Clinical experience with lonoctocog alfa for prophylaxis in a patient with hemophilia A. Tromboz, gemostaz i reologiya. 2025;(2):129–134. (In Russ.).

References

  1. Clinical guidelines — Hemophilia — 2023–2024–2025(04.05.2023). Moscow: Ministerstvo zdravoohraneniya Rossijskoj Federacii, 2023. 39 pp. (In Russ.). Available at: http://disuria.ru/_ld/12/1291_kr23D66D67MZ.pdf. [Accessed: 05.02.2025].
  2. Castaman G., Matino D. Hemophilia A and B: molecular and clinical similarities and differences. Haematologica. 2019;104(9):1702–9. DOI: 10.3324/haematol.2019.221093.
  3. Annual Global Survey. World Federation of Hemophilia, 2023. Available at: https://wfh.org/research-and-data-collection/annualglobal-survey/. [Accessed: 05.02.2025].
  4. Ozelo M.C., Yamaguti-Hayakawa G.G. Impact of novel hemophilia therapies around the world. Res Pract Thromb Haemost. 2022;6(3):e12695. DOI: 10.1002/rth2.12695.
  5. Zozulya N.I., Chernov V.M., Tarasova I.S., Rumyantsev A.G. Unsolved issues of providing medical care to patients with hemophilia with inhibitors in Russia. Rossijskij zhurnal detskoj gematologii i onkologii. 2019;6(2):48–53. (In Russ.). DOI: 10.21682/2311-1267-2019-6-2-48-53.
  6. Zozulya N.I., Dimitrieva O.S. Unsolved issues of treatment of adult patients with hemophilia A. Terapevticheskij arhiv. 2022;94(1):77–82. (In Russ.). DOI: 10.26442/00403660.2022.01.201321.
  7. Mahlangu J., Young G., Hermans C. et al. Defining extended half-life rFVIII-A critical review of the evidence. Haemophilia. 2018;24(3):348–58. DOI: 10.1111/hae.13438.
  8. Ay C., Napolitano M., Hassoun A. et al. Classification of recombinant factor VIII products and implications for clinical practice: а systematic literature review. Haemophilia. 2024;30(3):577–88. DOI: 10.1111/hae.15001.
  9. Instructions for Use: Advate (https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid = ea2d5efb-9cb9–4cbbad37–13cdd0930563), Octofactor (https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid = 3983d894–1dbe-48f5–92cc-48860a555642), Nuwiq (https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid = 47b47063-cac5–424f-9f79–63da37ca2ffb), Eloctate (https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid = 7f748b6c-3100–43d2–8128–98f99d8f74e2), Afstyla (https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid = 93570087–8793–4f25–856d-3d6f286d61e7), Adenovate (https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid = d2a5eb92– 232d-47e8-a617-b044b9118379). State Register of Medicines. (InRuss.).
  10. Guillet B., Hassoun A., Wibaut B. A French real-world evidence study evaluating the efficacy, safety, and pharmacokinetic parameters of rVIII-SingleChain in patients with hemophilia a receiving prophylaxis. Thromb Haemost. 2023;123(5):490–500. DOI: 10.1055/s-0043-1761449.
  11. Mahlangu J., Kuliczkowski K., Karim F.A. al.; AFFINITY Investigators. Efficacy and safety of rVIII-SingleChain: results of a phase 1/3 multicenter clinical trial in severe hemophilia A. Blood. 2016;128(5):630–7. DOI: 10.1182/blood-2016-01-687434.
  12. Stasyshyn O., Djambas Khayat C., Iosava G. et al. Safety, efficacy and pharmacokinetics of rVIII-SingleChain in children with severe hemophilia A: results of a multicenter clinical trial. J Thromb Haemost. 2017;15(4):636–44. DOI: 10.1111/jth.13647.